News

Vancomycin trial shows no significant reduction in recurrent C. diff infections
University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...
Infectious Disease Advisor4h
Tyzavan, a Ready-to-Infuse Vancomycin Formulation, Gets FDA Approval
The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.
MedPage Today on MSN7d
Preventive Vancomycin Shows Promise Against Recurrent C. Difficile
Vancomycin appeared to top placebo for lowering Clostridioides difficile infection (CDI) recurrence rates in patients taking ...
Healio9d
Fecal microbiota transplantation ‘at least as effective’ as vancomycin in C. difficile
Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile ...
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, ...
Monthly Prescribing Reference7d
Tyzavan, a Ready-to-Infuse Vancomycin Formulation, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Tyzavan ™ (vancomycin injection, USP), a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of ...
Fierce Pharma1d
Regulatory tracker: With FDA filing, J&J targets Caplyta expansion into schizophrenia relapse prevention
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
HealthDay on MSN7d
Fecal Microbiota Transplantation Could Be First-Line Therapy for C difficile
Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI).